Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,699 result(s) found for: Chemistry. Displaying page 85 of 85.
    «« First « Previous 77  78  79  80  81  82  83  84  85 
    EudraCT Number: 2009-015595-10 Sponsor Protocol Number: IC51-322 Start Date*: 2010-03-23
    Sponsor Name:Intercell AG
    Full Title: IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®, JESPECT®) IN A PEDIATRIC POPULATION IN NON‐ENDEMIC COUNTRIES. UNCONTROLLED, OPEN‐LABEL PHASE 3 STUDY
    Medical condition: Japanese Encephalitis (JE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10023120 Japanese B viral encephalitis LLT
    14.1 10021881 - Infections and infestations 10023122 Japanese B virus encephalitis LLT
    14.1 10021881 - Infections and infestations 10023119 Japanese B encephalitis LLT
    14.1 10021881 - Infections and infestations 10014596 Encephalitis Japanese B PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001699-39 Sponsor Protocol Number: HER117158 Start Date*: 2015-03-11
    Sponsor Name:GlaxoSmithKline Research Development Ltd
    Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva...
    Medical condition: Subjects with advanced HER3-positive solid tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033575 Pancreas cancer LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003341-25 Sponsor Protocol Number: IPP-201101/005 Start Date*: 2016-05-02
    Sponsor Name:ImmuPharma SA
    Full Title: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lup...
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005405-37 Sponsor Protocol Number: NH19960 Start Date*: 2006-06-28
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy
    Medical condition: Anemic patients undergoing chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Completed) CZ (Completed) EE (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004394-49 Sponsor Protocol Number: LIB003-007 Start Date*: 2021-08-12
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at ...
    Medical condition: Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001551-13 Sponsor Protocol Number: D0818C00001 Start Date*: 2013-08-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following ...
    Medical condition: BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003675-18 Sponsor Protocol Number: ANX005-wAIHA-02 Start Date*: 2021-01-11
    Sponsor Name:Annexon, Inc.
    Full Title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolyti...
    Medical condition: Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005078-70 Sponsor Protocol Number: ACTICCA-1 Start Date*: 2014-01-16
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) ...
    Medical condition: Cholangiocarcinoma and gallbladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017620 Gallbladder carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003595-12 Sponsor Protocol Number: ADVL1322-VEG116731 Start Date*: 2013-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors.
    Medical condition: relapsed solid tumours in children, adolescents and young adults.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA CZ (Completed) SK (Completed) ES (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003859-61 Sponsor Protocol Number: PM0259CA232J1 Start Date*: 2015-07-28
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy
    Medical condition: Advanced Non Small Lung Cancer unfit for a platinium-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed) HU (Completed) CZ (Completed) DE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020515-37 Sponsor Protocol Number: CFTY720D2399 Start Date*: 2010-08-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, open-label, multicenter study evaluating the long-term, safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multip...
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) GB (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) AT (Completed) GR (Completed) NL (Completed) IE (Completed) BE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2007-004277-26 Sponsor Protocol Number: GS-US-205-0110 Start Date*: 2008-04-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution (AZLI) versus Tobramycin Nebuliser Solution (TNS) in an Int...
    Medical condition: Adult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) GB (Completed) IE (Completed) DK (Completed) DE (Completed) NL (Completed) IT (Completed) PT (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019361-28 Sponsor Protocol Number: N01358 Start Date*: 2011-03-15
    Sponsor Name:UCB BioSciences Inc. A Member of the UCB Group of Companies
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (≥16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES
    Medical condition: Focal Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061334 Partial seizures PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) GB (Completed) SE (Completed) FR (Ongoing) FI (Completed) AT (Completed) NL (Completed) EE (Completed) LT (Completed) LV (Completed) HU (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-004753-14 Sponsor Protocol Number: 109MS303 Start Date*: 2009-01-22
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) DE (Completed) IE (Completed) LV (Completed) ES (Completed) FR (Completed) EE (Completed) GR (Completed) AT (Completed) NL (Completed) BG (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001254-29 Sponsor Protocol Number: I2R-MC-BIAM Start Date*: 2012-01-24
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, R...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Completed) LT (Completed) GR (Completed) IT (Completed) DK (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001980-19 Sponsor Protocol Number: 42756493BLC2002 Start Date*: 2018-04-25
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically...
    Medical condition: Metastatic or Surgically Unresectable Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001266-15 Sponsor Protocol Number: BRF115532 Start Date*: 2013-02-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 muta...
    Medical condition: High-risk BRAF V600 mutation-positive melanoma after surgical resection.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DE (Completed) NO (Completed) GB (Completed) AT (Completed) GR (Completed) IT (Completed) NL (Completed) DK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002089-11 Sponsor Protocol Number: CMBG453B12301 Start Date*: 2020-06-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodyspla...
    Medical condition: adult subjects with intermediate, high or very high risk (per IPSS-R prognostic risk categories) myelodysplastic syndrome or with Chronic Myelomonocytic Leukemia - 2 (CMML-2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) IT (Prematurely Ended) ES (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) FI (Prematurely Ended) LT (Completed) NL (Prematurely Ended) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 77  78  79  80  81  82  83  84  85 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 18:01:48 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA